This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
24
escalating doses
Jasper Clinic, Inc.
Kalamazoo, Michigan, United States
Measuring subject safety by collecting and evaluating vital signs, adverse events, and laboratory measures.
Time frame: 14 days
Measuring the level of ETC-1002 and its metabolite ESP15228 in the blood.
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.